Page 75 - 2021_07-Haematologica-web

TBI versus non-TBI regimens for de novo AML
References
1. Ishida H, Kato M, Kudo K, et al. Comparison of outcomes for pediatric patients with acute myeloid leukemia in remission and undergoing allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens based on either intravenous busulfan or total body irradiation: a report from the Japanese Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015;21(12):2141-2147.
2. Kinnunen U, Koistinen P, Ohtonen P, et al. Influence of chemotherapy courses on the rate of bloodstream infections during neu- tropenia in adult acute myeloid leukaemia. Scand J Infect Dis. 2008;40(8):642-647.
3.Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012;119(25): 5980-5988.
4. Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophos- phamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98(13): 3569-3574.
5. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradi- ation, and allogeneic marrow transplanta- tion. Blood. 1977;49(4):511-533.
6. Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remis- sion: a randomized trial of a busulfan- Cytoxan versus Cytoxan-total body irradia- tion as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood. 1992;79(10):2578-2582.
7. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allo- geneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002;8(3):145-154.
8.Pidala J, Kim J, Anasetti C, et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol. 2010;3:36.
9. Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophos- phamide in combination with busulfan
compared with TBI. Blood. 2013;122(24):
3863-3870.
10. Bredeson C, LeRademacher J, Kato K, et al.
Prospective cohort study comparing intra- venous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122(24):3871-3878.
11.Nakasone H, Fukuda T, Kanda J, et al. Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell trans- plantation. Bone Marrow Transplant. 2015;50(4):559-565.
12. Radhakrishnan K, Bishop J, Jin Z, et al. Risk factors associated with liver injury and impact of liver injury on transplantation- related mortality in pediatric recipients of allogeneic hematopoietic stem cell trans- plantation. Biol Blood Marrow Transplant. 2013;19(6):912-917.
13. Ustun C, Young JH, Papanicolaou GA, et al. Bacterial blood stream infections (BSIs), par- ticularly post-engraftment BSIs, are associat- ed with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019;54:1254-1265.
14. Dandoy CE, Ardura MI, Papanicolaou GA, et al. Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis. Bone Marrow Transplant. 2017;52(8):1091-1106.
15. Freycon F, Casagranda L, Trombert-Paviot B. The impact of severe late-effects after 12 Gy fractionated total body irradiation and allo- geneic stem cell transplantation for child- hood leukemia (1988-2010). Pediatr Hematol Oncol. 2019;36(16):86-102.
16. Bresters D, Lawitschka A, Cugno C, et al. Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really mat- ters. Bone Marrow Transplant. 2016;51(11): 1482-1489.
17. Faraci M, Barra S, Cohen A, et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow trans- plant. Int J Radiat Oncol Biol Phys. 2005;63 (5):1568-1575.
18. Bhatia S, Davies SM, Scott Baker K, et al. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges. Biol Blood Marrow Transplant. 2011;17(10):1428-1435.
19. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
20. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: associa- tion with treatment-related mortality and relapse. Blood. 2002;100(2):406-414.
21.
22.
Klein KP and Moeschberger ML. Survival analysis. techniques for censored and trun- cated data. Springer Science & Business Media. 2006.
Zhang X, Zhang MJ. SAS macros for estima- tion of direct adjusted cumulative Incidence curves under proportional subdistribution hazards models. Comput Methods Programs Biomed. 2011;101(1):87-93.
23. Zhang X, Loberiza FR, Klein JP, Zhang MJ. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed . 2007;88(2):95-101.
24. Commenges D, Andersen PK. Score test of homogeneity for survival data. Lifetime Data Anal. 1995;1(2):145-156.
25.Eapen M, Kurtzberg J, Zhang MJ, et al. Umbilical cord blood transplantation in chil- dren with acute leukemia: impact of condi- tioning on transplantation outcomes. Biol Blood Marrow Transplant. 2017;23(10): 1714-1721.
26. Wilhelmsson M, Vatanen A, Borgström B, et al. Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT-two decades of longitudinal follow-up. Bone Marrow Transplant. 2015;50(6):850- 857.
27. Vrooman LM, Millard HR, Brazauskas R, et al. Survival and late effects after allogeneic hematopoietic cell transplantation for hematologic malignancy at less than three years of age. Biol Blood Marrow Transplant. 2017;23(8):1327-1334.
28. Lucchini G, Labopin M, Beohou E, et al. Impact of conditioning regimen on out- comes for children with acute myeloid leukemia undergoing transplantation in first complete remission. An analysis on behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplant. Biol Blood Marrow Transplant. 2017;23(3):467-474.
29. Lee CJ, Kim S, Tecca HR, et al. Late effects after ablative stem cell transplantation for adolescents and young adults with acute myeloid leukemia. Blood Adv. 2020;4(6): 983-992.
30. Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplanta- tion for acute myeloid leukemia: time to move toward a minimal residual disease- based definition of complete remission? J Clin Oncol. 2016;34(4):329-336.
haematologica | 2021; 106(7)
1845